Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arsenic Trioxide in Pediatric Solid Tumors
NCT00024258Phase 2
Key facts
- Status
- Completed
- Start
- Mar 2001
- Primary completion
- May 2009
- Countries
- 1
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Modality
- DNA Intercalators/Alkylators
- Drugs
- arsenic trioxide
- Conditions
- neuroblastomaEwing sarcomaprimitive neuroectodermal tumor (PNET)retinoblastoma (Rb)Wilms tumor (WT)
01
Overview
Phase 2, open-label, single-arm trial of arsenic trioxide in neuroblastoma, Ewing sarcoma, primitive neuroectodermal tumor (PNET) and 8 more, sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Response Rate at 1 year. Started Mar 2001; status: completed.
02
Design
1 arm- Study design
- Non-randomizedOpen-label
Arsenic Trioxide
Arsenic trioxide IV
03
Who it enrols
Patients with histologically confirmed neuroblastoma or other pediatric solid tumors who have relapsed from or are resistant to prior standard therapy, aged 40 and under, with adequate organ function.
04
Endpoints
Primary
Response Rate
Secondary
Toxicity
Beyond the preview
Go deeper on NCT00024258.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00024258.